These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35961884)

  • 21. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database.
    Nagasu H; Yano Y; Kanegae H; Heerspink HJL; Nangaku M; Hirakawa Y; Sugawara Y; Nakagawa N; Tani Y; Wada J; Sugiyama H; Tsuruya K; Nakano T; Maruyama S; Wada T; Yamagata K; Narita I; Tamura K; Yanagita M; Terada Y; Shigematsu T; Sofue T; Ito T; Okada H; Nakashima N; Kataoka H; Ohe K; Okada M; Itano S; Nishiyama A; Kanda E; Ueki K; Kashihara N
    Diabetes Care; 2021 Nov; 44(11):2542-2551. PubMed ID: 34593566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
    Ruanpeng D; Ungprasert P; Sangtian J; Harindhanavudhi T
    Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28440590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Scheen AJ
    Clin Pharmacokinet; 2015 Jul; 54(7):691-708. PubMed ID: 25805666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors and Combined SGLT1/2 Inhibitors on Cardiovascular, Metabolic, Renal, and Safety Outcomes in Patients with Diabetes: A Network Meta-Analysis of 111 Randomized Controlled Trials.
    Teo YN; Ting AZH; Teo YH; Chong EY; Tan JTA; Syn NL; Chia AZQ; Ong HT; Cheong AJY; Li TY; Poh KK; Yeo TC; Chan MY; Wong RCC; Chai P; Sia CH
    Am J Cardiovasc Drugs; 2022 May; 22(3):299-323. PubMed ID: 35316484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Lajara R
    Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.
    Teo YH; Teo YN; Syn NL; Kow CS; Yoong CSY; Tan BYQ; Yeo TC; Lee CH; Lin W; Sia CH
    J Am Heart Assoc; 2021 Feb; 10(5):e019463. PubMed ID: 33625242
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
    Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
    Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of effects of sodium-glucose co-transporter 2 inhibitor in Japanese type 2 diabetes mellitus patients with chronic kidney disease.
    Kobayashi K; Toyoda M; Kimura M; Hatori N; Furuki T; Sakai H; Takihata M; Umezono T; Ito S; Suzuki D; Takeda H; Kanamori A; Degawa H; Yamamoto H; Machimura H; Mokubo A; Chin K; Obana M; Hishiki T; Aoyama K; Nakajima S; Umezawa S; Shimura H; Aoyama T; Sato K; Miyakawa M
    Diab Vasc Dis Res; 2019 Jan; 16(1):103-107. PubMed ID: 30284913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
    Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
    BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.
    Lee JY; Cho Y; Lee M; Kim YJ; Lee YH; Lee BW; Cha BS; Kang ES
    Diabetes Metab J; 2019 Apr; 43(2):158-173. PubMed ID: 30688052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of SGLT2 Inhibitors as the Fifth Drug in the Management of Type 2 Diabetes Mellitus in Asian Indians not Controlled with at least 4 Oral Antidiabetic Drugs.
    Panikar V; Joshi SR; Deogaonkar N; Vadgama J; Nasikkar N; Kamat T; Sheikh S; Jain CC; Wagle T
    J Assoc Physicians India; 2018 Dec; 66(12):46-49. PubMed ID: 31315325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.
    Carlson CJ; Santamarina ML
    Expert Opin Drug Saf; 2016 Oct; 15(10):1401-12. PubMed ID: 27449721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
    Brady JA; Hallow KM
    J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.
    Sen T; Li J; Neuen BL; Neal B; Arnott C; Parikh CR; Coca SG; Perkovic V; Mahaffey KW; Yavin Y; Rosenthal N; Hansen MK; Heerspink HJL
    Diabetologia; 2021 Oct; 64(10):2147-2158. PubMed ID: 34415356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
    Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
    Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review.
    Lin J; Wang S; Wen T; Zhang X
    Int Urol Nephrol; 2022 Sep; 54(9):2305-2316. PubMed ID: 35133574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.